Literature DB >> 26033427

Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.

R Kar1, J K Palanichamy, A Banerjee, P Chattopadhyay, S K Jain, N Singh.   

Abstract

PURPOSE: This aim of this study was to use ovarian cancer cells shed in ascitic fluid to establish primary cultures and subsequently use it to detect drug resistance to paclitaxel. Survivin siRNA was used to down regulate survivin expression and effect on paclitaxel resistance was also evaluated.
METHODOLOGY: Ascitic fluid along with corresponding primary tumor tissue was collected from twenty untreated epithelial ovarian cancer patients. Ten primary cultures were established from ascites obtained from untreated ovarian cancer patients in MCDB 105 and M199 medium (ratio 1:1). Knockdown of survivin was done using siRNA and sensitivity to paclitaxel was evaluated by MTT assay.
RESULTS: Grape-like clusters of ovarian cancer cells present in ascites attached and gave a characteristic cobble stone appearance. Treatment with survivin siRNA resulted in a fivefold decrease in survivin expression in primary cultures. Survivin siRNA treatment significantly increased the sensitivity of the primary ovarian cancer cell cultures to paclitaxel.
CONCLUSION: Ascitic cancer cells reflect the molecular profile of tumor and can be used to diagnose resistance to chemotherapy. This study also establishes that high survivin expression is also responsible for resistance to paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26033427     DOI: 10.1007/s12094-015-1302-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  18 in total

1.  Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients.

Authors:  Trevor G Shepherd; Brigitte L Thériault; Elizabeth J Campbell; Mark W Nachtigal
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Epithelial ovarian cancer: An overview.

Authors:  Arpita Desai; Jingyao Xu; Kartik Aysola; Yunlong Qin; Chika Okoli; Ravipati Hariprasad; Ugorji Chinemerem; Candace Gates; Avinash Reddy; Omar Danner; Geary Franklin; Anachebe Ngozi; Guilherme Cantuaria; Karan Singh; William Grizzle; Charles Landen; Edward E Partridge; Valerie Montgomery Rice; E Shyam P Reddy; Veena N Rao
Journal:  World J Transl Med       Date:  2014-04-12

3.  Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells.

Authors:  Zehua Wang; Yanhua Xie; Hongbo Wang
Journal:  Cancer Biol Ther       Date:  2005-07-02       Impact factor: 4.742

4.  Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis.

Authors:  Zhiyin Song; Xuebiao Yao; Mian Wu
Journal:  J Biol Chem       Date:  2003-03-26       Impact factor: 5.157

5.  Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

Authors:  Don S Dizon; Jakob Dupont; Sibyl Anderson; Paul Sabbatini; Amanda Hummer; Carol Aghajanian; David Spriggs
Journal:  Gynecol Oncol       Date:  2003-12       Impact factor: 5.482

6.  Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.

Authors:  Juan Li; Peishu Liu; Hongluan Mao; Ancong Wanga; Xiaolei Zhang
Journal:  Oncol Rep       Date:  2009-06       Impact factor: 3.906

7.  Increased survivin expression confers chemoresistance to tumor-associated endothelial cells.

Authors:  Jenilyn J Virrey; Shengxi Guan; Wei Li; Axel H Schönthal; Thomas C Chen; Florence M Hofman
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

8.  Survivin expression in ovarian cancer.

Authors:  Z Liguang; L Peishu; M Hongluan; J Hong; W Rong; M S Wachtel; E E Frezza
Journal:  Exp Oncol       Date:  2007-06

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Primary culture and mRNA analysis of human ovarian cells.

Authors:  Lesley D. Dunfield; Trevor G. Shepherd; Mark W. Nachtigal
Journal:  Biol Proced Online       Date:  2002-10-28       Impact factor: 3.244

View more
  7 in total

1.  Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells.

Authors:  Pornsiri Pitchakarn; Sonthaya Umsumarng; Sariya Mapoung; Pisamai Ting; Piya Temviriyanukul; Wanisa Punfa; Wilart Pompimon; Pornngarm Limtrakul
Journal:  J Nat Med       Date:  2017-06-21       Impact factor: 2.343

2.  Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.

Authors:  Rujia Fan; Yiying Wang; Yue Wang; Li Wei; Wenxin Zheng
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

3.  Characterization of ascites-derived tumor cells from an endometrial cancer patient.

Authors:  Xuelu Li; Dandan Zhu; Ning Li; Hui Yang; Zuowei Zhao; Man Li
Journal:  Cancer Sci       Date:  2017-10-25       Impact factor: 6.716

4.  Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin.

Authors:  Shengpeng Wang; Anqi Wang; Min Shao; Ligen Lin; Peng Li; Yitao Wang
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

5.  Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma.

Authors:  Xiyang Sun; Ying Chen; Hui Zhao; Guanglei Qiao; Meiyang Liu; Chunlei Zhang; Daxiang Cui; Lijun Ma
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

6.  Survivin Promotes Piperlongumine Resistance in Ovarian Cancer.

Authors:  Xing-Wei Nan; Li-Hua Gong; Xu Chen; Hai-Hong Zhou; Piao-Piao Ye; Yang Yang; Zi-Hao Xing; Meng-Ning Wei; Yao Li; Sheng-Te Wang; Kun Liu; Zhi Shi; Xiao-Jian Yan
Journal:  Front Oncol       Date:  2019-11-29       Impact factor: 6.244

7.  Dihydromyricetin Induces Apoptosis and Reverses Drug Resistance in Ovarian Cancer Cells by p53-mediated Downregulation of Survivin.

Authors:  Yingqi Xu; Shengpeng Wang; Hon Fai Chan; Huaiwu Lu; Zhongqiu Lin; Chengwei He; Meiwan Chen
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.